Real world data in mechanical thrombectomy: who are we losing to follow-up?
In: Journal of neurointerventional surgery, Jg. 16 (2024-04-23), Heft 5, S. 471-477
academicJournal
Zugriff:
Background: Missing outcome data (MOD) is a common problem in clinical trials and registries, and a potential bias when drawing conclusions from these data. Identifying factors associated with MOD may help to increase follow-up rates and assess the need for imputation strategies. We investigated MOD in a multicenter, prospective registry study of mechanical thrombectomy (MT) in large vessel occlusion ischemic stroke.
Methods: 13 082 patients enrolled in the German Stroke Registry-Endovascular Treatment from May 2015 to December 2021 were analyzed with regard to MOD (90 day modified Rankin Scale, mRS). Univariate logistic regression analyses identified factors unbalanced between patients with and without MOD. Subgroup analyses were performed to identify patients for whom increased efforts to perform clinical follow-up after hospital discharge are needed.
Results: We identified 19.7% (2580/13 082) of patients with MOD at the 90 day follow-up. MOD was more common with higher pre-stroke disability (mRS 3-5, 32.2% vs mRS 0-2, 13.7%; P<0.001), absence of bridging intravenous thrombolysis, longer time to treatment, and in patients with high post-stroke disability at discharge (mRS 3-5 vs 0-2: OR 1.234 (95% CI 1.107 to 1.375); P<0.001). In contrast, MOD was less common with futile recanalization (thrombolysis in cerebral infarction (TICI) score of 0-2a, 12.4% vs TICI 2b-3, 15.0%; P=0.001). In patients discharged alive with well documented baseline characteristics, shorter hospital stay (OR 0.992 (95% CI 0.985 to 0.998); P=0.010) and discharge to institutional care or hospital (OR 1.754 (95% CI 1.558 to 1.976); P<0.001) were associated with MOD.
Conclusion: MOD in routine care MT registry data was not random. Increased efforts to perform clinical follow-up are needed, especially in the case of higher pre-stroke and post-stroke disability and discharge to hospital or institutional care.
Trial Registration: NCT03356392.
Competing Interests: Competing interests: AO reports speakers bureau from Cerenovus and Canon Medical. KG reports personal fees and/or non-financial support from Bayer, Boehringer Ingelheim, Bristol-Meyers Squibb, Daiichi Sankyo, and Pfizer. MH reports personal fees from Bristol-Meyers Squibb, outside of the submitted work. TU reports personal fees from Merck Serono and Pfizer, and grants from Else Kröner-Fresenius Stiftung.
(© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Titel: |
Real world data in mechanical thrombectomy: who are we losing to follow-up?
|
---|---|
Autor/in / Beteiligte Person: | Hahn, M ; Gröschel, S ; Othman, A ; Brockstedt, L ; Civelek, A ; Brockmann, MA ; Gröschel, K ; Uphaus, T |
Zeitschrift: | Journal of neurointerventional surgery, Jg. 16 (2024-04-23), Heft 5, S. 471-477 |
Veröffentlichung: | London : BMJ Publishing Group, c2009-, 2024 |
Medientyp: | academicJournal |
ISSN: | 1759-8486 (electronic) |
DOI: | 10.1136/jnis-2023-020435 |
Schlagwort: |
|
Sonstiges: |
|